News Detail
Ahmedabad, 2 June 2023: After finding lapses in data integrity and GMP compliance at one of the facilities of Intas Pharmaceuticals Ltd, the US Food and Drug Administration (US FDA) on Thursday issued an ‘Import Alert’ on the plant located at Metoda near Ahmedabad.
Source : The Hindu BusinessLine
Intas Pharma
USFDA
Import Alert
Metoda plant
good manufacturing practices
data integrity
Related News
- Critical medicines for cancer, diabetes set to get expensive as govt clears price hike, say sources (27-03-2025)
- DGFT proposes mandatory GST E-Invoices for pharma export benefits (27-03-2025)
- US FDA approves first treatment for rare genetic disorder Prader-Willi syndrome (27-03-2025)
- FDA approves GSK’s 'Blujepa' for uncomplicated UTIs (27-03-2025)
- Bengal drug control publishes helpline to report fake medicines (27-03-2025)
- Misleading ads: SC asks states UTs to set up grievance redressal mechanism (26-03-2025)
- WHO partners with regulators, experts to strengthen safety and access of medical devices (26-03-2025)
- PCI warns of tough action against inspectors who don't follow its guidelines during inspection (26-03-2025)
- Seizure of fake Human Albumin Vials rings alarm bells (26-03-2025)
- Pharmacy owner, three others held for illegal sale of intoxication drug (26-03-2025)